The World Health Organization (WHO) announced on Thursday its support for weight loss drugs worldwide.
The organization plans to support the LPG-1 such as Wogovy and Zepbound to treat obesity in adults as part of a change in the address of the global obesity epidemic, as reported by Reuters.
In a memorandum, the agency requested strategies to improve access to medicines in low and medium -sized countries, Reuters summarized.
Oatzempic ‘diet to lose weight: Does it work and is it safe?
More than one billion people have obesity worldwide, according to WHO data, and about 70% of these people live in low and medium -sized countries.
The proven effectiveness of drugs for weight loss has led people, especially in the United States and other high-income countries such as Great Britain and Germany, to look for LPG-1 solutions.
For more lifestyle, visit Foxnews.com/lifestyle
However, the cost can be a factor, since medications can have a price of more than $ 1,000 per month, Reuters said.
In a statement, a WHO spokesman wrote that the agency has been working on a “set of new recommendations for the prevention of obesity, care and treatment” among the different age groups, including children, adolescents and adults.
Click here to register in our lifestyle bulletin
The agency said that drug recommendations are completed in August or September 2025.
The guide will also include “how and when this kind of medications can be integrated as a component of a chronic care model that includes clinical and lifestyle interventions,” said WHO.
WHO experts also plan to meet next week to decide whether GLP-1 medications should be included in the agency’s essential medicines to treat both obesity and type 2 diabetes.
According to reports, the agency also requests longer -term studies on the profitability of these medications “in all environments” and income states.
